{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:30:09Z","timestamp":1793464209807,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40261-026-01555-x","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:11:58Z","timestamp":1786608718000},"page":"1255-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Real-World Comparison of Adherence, Persistence, Health-Care Utilization, and Costs Among Biologics for Moderate-to-Severe Psoriasis in China"],"prefix":"10.1007","volume":"46","author":[{"given":"Xiaoning","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-2785","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"10281","key":"1555_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/s0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"19","key":"1555_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1555_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1541292","volume":"13","author":"K Yu","year":"2025","unstructured":"Yu K, Cao C, An F, Xu A, Wu X. Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021. Front Public Health. 2025;13:1541292. https:\/\/doi.org\/10.3389\/fpubh.2025.1541292.","journal-title":"Front Public Health"},{"issue":"28","key":"1555_CR4","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.18453","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Wang G, Jin H, Xu J, Zhu X, Zheng M, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381\u20139. https:\/\/doi.org\/10.18632\/oncotarget.18453.","journal-title":"Oncotarget"},{"issue":"1","key":"1555_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329066","volume":"21","author":"CJ Che Awanis","year":"2026","unstructured":"Che Awanis CJ, Norhayati MN, Mat Yudin Z. Beyond the skin: lived experiences and coping strategies of psoriasis patients in Malaysia. PLoS ONE. 2026;21(1):e0329066. https:\/\/doi.org\/10.1371\/journal.pone.0329066.","journal-title":"PLoS ONE"},{"key":"1555_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62010164","author":"A Arn\u012bte","year":"2026","unstructured":"Arn\u012bte A, Bondare-Ansberga V, Reinberga L, Hartmane I, Mika\u017e\u0101ns I. Depression, anxiety and quality of life in patients with atopic dermatitis and psoriasis. Medicina (Kaunas). 2026. https:\/\/doi.org\/10.3390\/medicina62010164.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"1555_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650-6.e3. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.028.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s13555-025-01472-5","volume":"15","author":"A Shi","year":"2025","unstructured":"Shi A, Shu Y, Haddad JE, Wu S, Smayra K, Sudesh SM, et al. Cardiovascular and kidney outcomes after systemic treatment for plaque psoriasis: a systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2025;15(9):2455\u201382. https:\/\/doi.org\/10.1007\/s13555-025-01472-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1555_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2247106","volume":"34","author":"S Min","year":"2023","unstructured":"Min S, Wang D, Xia J, Lin X, Jiang G. The economic burden and quality of life of patients with psoriasis treated with biologics in China. J Dermatolog Treat. 2023;34(1):2247106. https:\/\/doi.org\/10.1080\/09546634.2023.2247106.","journal-title":"J Dermatolog Treat"},{"issue":"Pt 1","key":"1555_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113388","volume":"143","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Verduci C, Laconi E, Mangione A, Dondi C, Del Vecchio M, et al. Current therapeutic overview and future perspectives regarding the treatment of psoriasis. Int Immunopharmacol. 2024;143(Pt 1):113388. https:\/\/doi.org\/10.1016\/j.intimp.2024.113388.","journal-title":"Int Immunopharmacol"},{"key":"1555_CR11","unstructured":"National Medical Products Administration (NMPA). Official website of the National Medical Products Administration; [cited 2026 Feb 23]. Available from: http:\/\/www.nmpa.gov.cn\/."},{"key":"1555_CR12","unstructured":"National Healthcare Security Administration (NHSA). 2025 Niandu yibao tanpan shouguan: dui zhen chuangxin biaoda \u201czhen zhichi\u201d [2025 health insurance negotiations conclude: expressing \u201cgenuine support\u201d for real innovation]. [cited 2026 Feb 23]. Available from: https:\/\/www.nhsa.gov.cn\/art\/2025\/11\/7\/art_14_18559.html"},{"issue":"3","key":"1555_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000519176","volume":"238","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Drug adherence and persistence of patients with moderate to severe psoriasis treated with biologic medications in a US commercially insured population. Dermatology. 2022;238(3):438\u201347. https:\/\/doi.org\/10.1159\/000519176.","journal-title":"Dermatology"},{"issue":"6","key":"1555_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904. https:\/\/doi.org\/10.1007\/s40257-022-00722-y.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1555_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/ijd.14429","volume":"58","author":"T Lunder","year":"2019","unstructured":"Lunder T, Zorko MS, Kolar NK, Suhodolcan AB, Marovt M, Leskovec NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6):631\u201341. https:\/\/doi.org\/10.1111\/ijd.14429.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1555_CR16","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","volume":"39","author":"C Leonardi","year":"2022","unstructured":"Leonardi C, Zhu B, Malatestinic WN, Eastman WJ, Guo J, Murage MJ, et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan\u00ae databases. Adv Ther. 2022;39(7):3214\u201324. https:\/\/doi.org\/10.1007\/s12325-022-02155-9.","journal-title":"Adv Ther"},{"issue":"11","key":"1555_CR17","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101\u201312. https:\/\/doi.org\/10.1111\/jdv.18409.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1555_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317. https:\/\/doi.org\/10.1111\/1346-8138.16543.","journal-title":"J Dermatol"},{"issue":"4","key":"1555_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.18553\/jmcp.2018.18308","volume":"25","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large US claims database. J Manag Care Spec Pharm. 2019;25(4):479\u201388. https:\/\/doi.org\/10.18553\/jmcp.2018.18308.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"1555_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.35541\/cjd.20210643","volume":"12","author":"Chinese Society of Dermatology CDA","year":"2021","unstructured":"Chinese Society of Dermatology CDA, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China (2021). Chin J Dermatol. 2021;12:1033\u201347. https:\/\/doi.org\/10.35541\/cjd.20210643.","journal-title":"Chin J Dermatol"},{"issue":"2","key":"1555_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09546634.2019.1698699","volume":"32","author":"SR Feldman","year":"2021","unstructured":"Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, et al. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2021;32(2):203\u201311. https:\/\/doi.org\/10.1080\/09546634.2019.1698699.","journal-title":"J Dermatolog Treat"},{"key":"1555_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01064-1","volume":"29","author":"Y Tada","year":"2023","unstructured":"Tada Y, Soliman AM, Ishii K, Sakuma R, Puig L, Davis M, et al. Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. Dermatol Ther. 2023;29:29. https:\/\/doi.org\/10.1007\/s13555-023-01064-1.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1555_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18553\/jmcp.2015.21.3.201","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201\u20139. https:\/\/doi.org\/10.18553\/jmcp.2015.21.3.201.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1555_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: A retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379. https:\/\/doi.org\/10.1007\/s40257-021-00598-4.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1555_CR26","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/jdv.13682","volume":"30","author":"P Davila-Seijo","year":"2016","unstructured":"Davila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, et al. Survival of classic and biological systemic drugs in psoriasis: Results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30(11):1942\u201350. https:\/\/doi.org\/10.1111\/jdv.13682.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01555-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:39:54Z","timestamp":1793461194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01555-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01555-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WX is an employee of Bristol-Myers Squibb. HX, XX, and WJ have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Academic Ethics Committee at Tianjin University (approval no. TJU-2024-309) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived owing to the retrospective nature of the study. Data were properly anonymized before the analysis.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available owing to policy restriction but are available from the corresponding author on reasonable request. The data that support the findings of this study are available from Inspur Co., Ltd., but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. However, data are available from the authors upon reasonable request and with permission of Inspur Co., Ltd.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WJ: conceptualization, supervision, methodology, review and editing; HX, XX: writing\u2014original draft, writing\u2014review and editing, data curation, formal analysis; WX: resources, review and editing. All authors read and approved the final version and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}